Regulatory Index News w/c 7 January 2019

Here is a selection of this week's latest news from around the world


Eli Lilly to buy Loxo Oncology for $8 billion

Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8 billion.

To read more follow this PharmaTimes link 


Pharma DTC spending outpaces rest of medical marketing, JAMA study finds

Spending on most methods of medical marketing grew in the past two decades, but direct-to-consumer advertisements increased the fastest, a comprehensive analysis published Tuesday in JAMA found.

To read more follow this BioPharmaDive link


Sage soars on success of postpartum depression drug

One of Sage Therapeutics' pipeline assets scored an early victory in a late-stage study of postpartum depression patients, spurring a nearly 43% spike in the Cambridge, Massachusetts-based biotech's stock.

To read more follow this BioPharmaDive link


Caritas Neuro Solutions & Innvocept team up

Edinburgh, Scotland-based mental health and neurology research company Caritas Neuro Solutions has signed a landmark partnership agreement with Mumbai, India-based digitally driven organisation Innvocept Solutions, enabling expansion of the company as a global player.

To read more follow this PharmaTimes link


Three men sentenced for supply of illicit meds

Three people have been handed custodial sentences in England for their involvement in the illegal supply of potentially dangerous prescription-only medicines.

To read more follow this PharmaTimes link


Pain, depression and antipsychotics drum up enthusiasm

SAN FRANCISCO — Therapies for central nervous system disorders competed for the limelight at the J.P. Morgan Healthcare Conference this week against the backdrop of big cancer deals — and held their own.

To read more follow this BioPharmaDive link




Lorna Osborn

Date Published

10th January 2019

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message